OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
NEW YORK, May 01, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.
Intercept management will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
- Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
- UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
- Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
